---
title: "NHS National Pharmaceuticals - Everolimus and terminated agreement products"
ocid: "ocds-h6vhtk-02a471"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02a471"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-02a471.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-02a471.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)"
published: "2021-09-28"
---

# NHS National Pharmaceuticals - Everolimus and terminated agreement products

Buyer: THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)  
Current stage: Award  
OCID: ocds-h6vhtk-02a471

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02a471)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-02a471.json)

## Summary

The procurement process initiated by the NHS Commissioning Board (operating under NHS England) involves a tender titled "NHS National Pharmaceuticals - Everolimus and terminated agreement products," which falls under the pharmaceutical products category (CPV code 33600000). The procurement is currently in the active stage, with potential call-offs across various regions set to commence as soon as possible, with the end dates for different products ranging from January to March 2022. The total estimated value for this framework agreement is approximately £18.72 million. Interested suppliers must submit their bids electronically via the specified eTendering portal before the tender period ends on 26 April 2021.

This tender presents significant opportunities for growth in the pharmaceutical sector, particularly for small and medium-sized enterprises (SMEs) offering products such as Everolimus and related goods. Companies focused on high-quality pharmaceuticals are well-suited to compete, especially given the NHS's ongoing demand for competitive supply and products related to critical care medicines. Businesses that can demonstrate compliance with the selection criteria and provide exceptional value in their offerings may find this tender to be a pathway to securing contracts within the NHS framework.

## Notice

Potential periods of call-offs under the framework agreement:Everolimus: All regions: to commence as soon as possible with an end date of 01/03/2022Oral Products: All regions: to commence as soon as possible with an end date of 28/02/2022Hospital Only Products: DLS, DNE, DNW, DLN and DSW regions: to commence as soon as possible with an end date 31/01/2022

### Lot Information

Lot 1 - CM/PHG/21/5632/00 Everolimus

Invitation to offer for NHS National Pharmaceuticals - Everolimus and terminated agreement productsOffer reference number: CM/PHG/21/5632/00Period of framework agreement: Start date to be confirmed with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.Potential periods of call-offs under the framework agreement:Everolimus: All regions: to commence as soon as possible with an end date of 01/03/2022. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Lot 2 - CM/PHG/21/5632/01 Oral (plus non parenteral) products

Invitation to offer for NHS National Pharmaceuticals - Everolimus and terminated agreement productsOffer reference number: CM/PHG/21/5632Period of framework agreement: Start date to be confirmed with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.Potential periods of call-offs under the framework agreement:Oral Products: All regions: to commence as soon as possible with an end date of 28/02/2022. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Lot 3 - CM/PHG/21/5632/02 Hospital Only products

Invitation to offer for NHS National Pharmaceuticals - Everolimus and terminated agreement productsOffer reference number: CM/PHG/21/5632Period of framework agreement: Start date to be confirmed with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.Potential periods of call-offs under the framework agreement:Hospital Only Products: DLS, DNE, DNW, DLN and DSW regions: to commence as soon as possible with an end date 31/01/2022. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/024061-2021 |
| Notice type | Tender Notice |
| Procurement type | Framework |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | Large, SME |
| All stages | Tender, Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 28 Sep 2021 |
| Submission deadline | 26 Apr 2021 |
| Future notice date | Not specified |
| Award date | 7 Jun 2021 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | £18,720,512 |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £1 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Cancelled |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND) |
| Locality | RUNCORN |
| Post town | Warrington |
| Postcode | WA7 2ES |
| Country | England |
| ITL 1 | TLD North West (England) |
| ITL 2 | TLD7 Merseyside |
| ITL 3 | TLD71 East Merseyside |
| Local authority | Halton |
| Electoral ward | Halton Lea |
| Westminster constituency | Runcorn and Helsby |
| Delivery location | Not specified |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 15 |
| Supplier names | ACCORD-UK; BOWMED IBISQUS; BRISTOL LABORATORIES; CRESCENT PHARMA; DR.REDDY'S LABORATORIES (UK; DRUGSRUS; FRESENIUS KABI; MARTINDALE PHARMA; MEDREICH; MILPHARM LTD/AUROBINBDO; MYLAN; RANBAXY; SELECTIVE SUPPLIES; TEVA; TORRENT PHARMA |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33600000 - Pharmaceutical products

## Release History

- 28 Sep 2021 at 11:36 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/024061-2021
- 9 Apr 2021 at 14:35 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/007424-2021

## Notice URLs

- http://health.atamis.co.uk
- http://health.atamis.co.ukCandidates
- https://supplierregistration.cabinetoffice.gov.ukand
- https://www.england.nhs.uk/
- https://www.gov.uk/courts-tribunals

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02a471. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-02a471.json.